These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet aggregation by the cAMP-phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase. Nishikawa M; Komada F; Morita K; Deguchi K; Shirakawa S Cell Signal; 1992 Jul; 4(4):453-63. PubMed ID: 1329900 [TBL] [Abstract][Full Text] [Related]
4. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. Hambleton R; Krall J; Tikishvili E; Honeggar M; Ahmad F; Manganiello VC; Movsesian MA J Biol Chem; 2005 Nov; 280(47):39168-74. PubMed ID: 16172121 [TBL] [Abstract][Full Text] [Related]
5. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Sun B; Li H; Shakur Y; Hensley J; Hockman S; Kambayashi J; Manganiello VC; Liu Y Cell Signal; 2007 Aug; 19(8):1765-71. PubMed ID: 17482796 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Ko WC; Shih CM; Lai YH; Chen JH; Huang HL Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Minami N; Suzuki Y; Yamamoto M; Kihira H; Imai E; Wada H; Kimura Y; Ikeda Y; Shiku H; Nishikawa M Life Sci; 1997; 61(25):PL 383-9. PubMed ID: 9416770 [TBL] [Abstract][Full Text] [Related]
9. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase. Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293 [TBL] [Abstract][Full Text] [Related]
10. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62). Liao CH; Tzeng CC; Teng CM Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503 [TBL] [Abstract][Full Text] [Related]
11. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473 [TBL] [Abstract][Full Text] [Related]
12. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Umekawa H; Tanaka T; Kimura Y; Hidaka H Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810 [TBL] [Abstract][Full Text] [Related]
13. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Manns JM; Brenna KJ; Colman RW; Sheth SB Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792 [TBL] [Abstract][Full Text] [Related]
16. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982 [TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Lindgren S; Rascón A; Andersson KE; Manganiello V; Degerman E Biochem Pharmacol; 1991 Jul; 42(3):545-52. PubMed ID: 1650216 [TBL] [Abstract][Full Text] [Related]
18. 2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities. Koga Y; Kihara Y; Okada M; Inoue Y; Tochizawa S; Toga K; Tachibana K; Kimura Y; Nishi T; Hidaka H Bioorg Med Chem Lett; 1998 Jun; 8(12):1471-6. PubMed ID: 9873372 [TBL] [Abstract][Full Text] [Related]
19. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects. Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790 [TBL] [Abstract][Full Text] [Related]
20. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Zhang W; Colman RW Blood; 2007 Sep; 110(5):1475-82. PubMed ID: 17392505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]